Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 8;14(1):108.
doi: 10.1186/s13045-021-01121-2.

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Umair Majeed  1 , Rami Manochakian  1 , Yujie Zhao  1 , Yanyan Lou  2
Affiliations
Review

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Umair Majeed et al. J Hematol Oncol. .

Abstract

Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher lung cancer into the era of personalized medicine, with the patient getting individualized treatment based on these markers. This review summarizes the recent advances in advanced NSCLC targeted therapy, focusing on first-in-human and early phase I/II clinical trials in patients with advanced disease. We have divided our discussion into different topics based on these agents' mechanisms of action. This article is aimed to be the most current review of available and upcoming targeted NSCLC treatment options. We will also summarize the currently available phase I/II clinical trial for NSCLC patients at the end of each section.

Keywords: Advanced NSCLC; First-in-human; Lung cancer; Phase I/II clinical trials; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Yanyan Lou: Advisory board: AstraZeneca, Novocure, Janssen Pharmaceuticals. Consultant: AstraZeneca. Honorarium: clarion health care. Research Funding Support: Merck, MacroGenics, Tolero Pharmaceuticals, AstraZeneca, Vaccinex, Blueprint Medicines, Harpoon Therapeutics, Sun Pharma Advanced Research, Bristol-Myers Squibb, Kyowa Pharmaceuticals, Tesaro, Bayer HealthCare. Rami Manochakian: Advisory Boards: Astra Zeneca, Guardant Health, Novocure, Takeda. Consulting: AstraZeneca. Yujie Zhao: Research Funding Support: Zai Lab, PDS Biotechnology, Transgen, Umair Majeed: None.

Figures

Fig. 1
Fig. 1
Mechanisms of acquired resistance to first-generation tyrosine kinase inhibitors (gefitinib and erlotinib) [22]. EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; MET, mesenchymal–epithelial transition factor; EMT, epithelial–mesenchymal transition; SCLC, small-cell lung cancer
Fig. 2
Fig. 2
Mechanisms of acquired resistance to osimertinib [22]. EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition factor; HER2, human epidermal growth factor receptor 2; FGFR1, fibroblast growth factor receptor 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; PIK3CA, phosphoinositide-3-kinase P110α catalytic subunit; SCLC, small-cell lung cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. ACSCFFAACS. American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020.
    1. Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
    1. Yuan M, Huang L-L, Chen J-H, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4(1):61. doi: 10.1038/s41392-019-0099-9. - DOI - PMC - PubMed
    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi: 10.1056/NEJMoa1916623. - DOI - PMC - PubMed

Publication types

MeSH terms